Welcome to our dedicated page for Taiwan Liposome Company, Ltd.c news (Ticker: TLC), a resource for investors and traders seeking the latest updates and insights on Taiwan Liposome Company, Ltd.c stock.
TLC (undefined) is a leader in developing innovative healthcare solutions, specializing in advanced drug delivery systems and pharmaceutical technologies. This dedicated news hub provides investors and industry observers with timely updates on the company's financial performance, research breakthroughs, and strategic initiatives.
Access authoritative information on TLC's clinical trials in oncology and neurology, partnership announcements with major pharmaceutical organizations, and progress in sustainable manufacturing practices. The curated news collection covers earnings reports, product launches, regulatory milestones, and corporate responsibility updates.
With a focus on transparent reporting, this resource serves as your primary destination for understanding TLC's market position and innovation pipeline. Content is rigorously maintained to support informed analysis of the company's growth trajectory in biotechnology and healthcare sectors.
Bookmark this page for streamlined access to verified updates about TLC's drug development progress, financial health, and industry collaborations. Check regularly for new insights into how the company continues to shape medical technology through its flagship transdermal delivery systems and R&D investments.
TLC (Nasdaq: TLC, TWO: 4152) reported a significant 214.2% increase in operating revenue for Q1 2021, totaling NT$37.6 million (US$1.3 million), compared to NT$12.0 million in Q1 2020. However, the net loss widened slightly to NT$218.2 million (US$7.7 million), a loss per share of NT$2.39 (US$0.08). Operating expenses rose by 13.0% to NT$253.8 million (US$8.9 million). The company maintained NT$1,080.0 million (US$37.9 million) in cash as of March 31, 2021. TLC is progressing with pivotal clinical trials and upcoming meetings with the FDA, alongside gaining recognition in corporate governance.
TLC has been recognized as a leader in corporate governance, ranking in the Top 5% among all Taiwan Stock Exchange and Taipei Exchange listed companies for the seventh consecutive year. This achievement underscores TLC's commitment to high standards in governance practices, particularly notable as it is the only biotech firm to secure this honor. Additionally, TLC ranks in the Top 5% of small and medium-sized enterprises with a market value of TWD 5-10 billion. The recognition will be honored at an award ceremony in June, alongside other top performers.
InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC), has announced its participation at the 23rd International Society for Aerosols in Medicine (ISAM) Congress, presenting a poster on the advantages of its inhalable formulations ISPM21 and ISPM19. The presentation, titled 'A Strategy to Treat COVID-19 with Targeted Delivery of Inhalable Liposomal Antiviral Drugs,' will take place in Boise, Idaho, from May 22-26, 2021. ISPM21 is a liposomal formulation of GS-441524, and ISPM19 is based on hydroxychloroquine, both aimed at improving treatment accessibility for COVID-19.
TLC (NASDAQ: TLC, TWO: 4152), a clinical-stage pharmaceutical company, announced its participation in two upcoming virtual investor conferences. The HC Wainwright & Co Global Life Sciences Conference is scheduled for March 9-10, 2021, with on-demand presentations available from 7am ET on March 9. The Oppenheimer 31st Annual Healthcare Conference will take place on March 16-17, 2021, featuring a presentation on March 17 at 8am ET. TLC's corporate presentation will be accessible on their website.
TLC (Nasdaq: TLC, TWO: 4152) reported a net loss of NT$983.3 million (US$35.0 million) for the fiscal year 2020, up from NT$807.5 million (US$27.0 million) in 2019. Operating revenue fell by 51.3% to NT$101.9 million (US$3.6 million), while operating expenses rose by 8.4% to NT$1,113.3 million (US$39.6 million). Despite these challenges, TLC achieved significant milestones in its clinical trials, including completing patient enrollment for its osteoarthritis program and advancing its inhalable hydroxychloroquine treatment. The company also strengthened its financial position with NT$1,342.7 million (US$47.8 million) in cash as of December 31, 2020.
TLC (Nasdaq: TLC, TWO: 4152) has announced the enrollment of the first subject in its Phase I clinical trial for TLC19, an inhaled formulation of hydroxychloroquine (HCQ) targeting COVID-19. This randomized, blinded study aims to assess the safety and pharmacokinetics of TLC19 in 30 healthy volunteers at varying doses. Labeled as a promising approach, TLC19 demonstrated significant lung exposure in preclinical studies, potentially enhancing efficacy while minimizing systemic toxicity. The company is also progressing on GMP manufacturing for large-scale production in Taiwan and the U.S.
TLC (Nasdaq: TLC, TWO: 4152) has received ethical and scientific approval for its Phase I clinical trial of TLC19, a novel inhalation therapy targeting COVID-19. The trial will assess safety, tolerability, and pharmacokinetics of inhaled TLC19 in healthy volunteers. The recent approval follows the acceptance of TLC's IND application with Taiwan's FDA. This initiative is part of Taiwan's 'Taiwan Can Help' strategy, aiming to provide effective treatments amidst the pandemic. The study is expected to yield critical data for future COVID-19 patient trials.
SOUTH SAN FRANCISCO and TAIPEI, Sept. 21, 2020 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company, announced that President George Yeh and CMO Dr. George Spencer-Green will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 23, 2020, at 9:10am ET. The 40-minute presentation will cover company updates and data analyses on its pain programs, TLC599 and TLC590. The corporate presentation is accessible on the TLC website.
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, September 11, 2020 – TLC (Nasdaq: TLC, TWO: 4152) announced that President George Yeh will participate in a fireside chat with analyst Kristen Kluska at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 10:00 AM ET. The discussion will focus on TLC's ongoing projects, including TLC599 for osteoarthritis pain relief, TLC590 for postsurgical pain, and TLC19 for COVID-19 treatment and prevention. A recording will be available on TLC's website.
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company, announced that its President, Mr. George Yeh, and Chief Medical Officer, Dr. George Spencer-Green, will present at HC Wainwright & Co’s 22nd Annual Global Investment Conference on September 14, 2020, at 10:00am ET. The presentation will cover company updates and analyses on pain programs TLC599 and TLC590. The corporate slide deck will be accessible on TLC’s website in the Investors section.
